Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2016, Article ID 6803098, 14 pages
http://dx.doi.org/10.1155/2016/6803098
Review Article

Dengue Fever: Causes, Complications, and Vaccine Strategies

1International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India
2Department of Biochemistry, University of Delhi, Institute of Home Economics, Hauz Khas, New Delhi 110016, India

Received 14 March 2016; Revised 18 May 2016; Accepted 1 June 2016

Academic Editor: Mario Clerici

Copyright © 2016 Niyati Khetarpal and Ira Khanna. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Chen and N. Vasilakis, “Dengue-Quo Tu et Quo Vadis?” Viruses, vol. 3, no. 9, pp. 1562–1608, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. B. R. Murphy and S. S. Whitehead, “Immune response to dengue virus and prospects for a vaccine,” Annual Review of Immunology, vol. 29, pp. 587–619, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Gubler, “Dengue/dengue haemorrhagic fever: history and current status,” Novartis Foundation Symposium, vol. 277, pp. 3–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. Sanofi Pasteur Media Release, http://www.sanofipasteur.com/en/articles/First-Vaccinations-against-Dengue-Mark-Historic-Moment-in-Prevention-of-Infectious-Diseases.aspx.
  5. World Health Organization, Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, WHO, Geneva, Switzerland, 2009.
  6. S. Bhatt, P. W. Gething, O. J. Brady et al., “The global distribution and burden of dengue,” Nature, vol. 496, no. 7446, pp. 504–507, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. O. J. Brady, P. W. Gething, S. Bhatt et al., “Refining the global spatial limits of dengue virus transmission by evidence-based consensus,” PLoS Neglected Tropical Diseases, vol. 6, no. 8, Article ID e1760, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. G. N. Malavige, S. Fernando, D. J. Fernando, and S. L. Seneviratne, “Dengue viral infections,” Postgraduate Medical Journal, vol. 80, no. 948, pp. 588–601, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. D. Stanaway, D. S. Shepard, E. A. Undurraga et al., “The global burden of dengue: an analysis from the Global Burden of Disease Study 2013,” The Lancet Infectious Diseases, vol. 16, no. 6, pp. 712–723, 2016. View at Publisher · View at Google Scholar
  10. G. Rezza, “Aedes albopictus and the reemergence of dengue,” BMC Public Health, vol. 12, article 72, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Perera and R. J. Kuhn, “Structural proteomics of dengue virus,” Current Opinion in Microbiology, vol. 11, no. 4, pp. 369–377, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Apte-Sengupta, D. Sirohi, and R. J. Kuhn, “Coupling of replication and assembly in flaviviruses,” Current Opinion in Virology, vol. 9, pp. 134–142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Kuhn, W. Zhang, M. G. Rossmann et al., “Structure of dengue virus: implications for flavivirus organization, maturation, and fusion,” Cell, vol. 108, no. 5, pp. 717–725, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Perera, M. Khaliq, and R. J. Kuhn, “Closing the door on flaviviruses: entry as a target for antiviral drug design,” Antiviral Research, vol. 80, no. 1, pp. 11–22, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Modis, S. Ogata, D. Clements, and S. C. Harrison, “Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein,” Journal of Virology, vol. 79, no. 2, pp. 1223–1231, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. R. de Alwis, M. Beltramello, W. B. Messer et al., “In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection,” PLoS Neglected Tropical Diseases, vol. 5, no. 6, Article ID e1188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. W. B. Messer, R. de Alwis, B. L. Yount et al., “Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 5, pp. 1939–1944, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. R. De Alwis, S. A. Smith, N. P. Olivarez et al., “Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7439–7444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Fibriansah, K. D. Ibarra, T.-S. Ng et al., “Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers,” Science, vol. 349, no. 6243, pp. 88–91, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Watanabe, K. W. K. Chan, J. Wang, L. Rivino, S.-M. Lok, and S. G. Vasudevan, “Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice,” Journal of Virology, vol. 89, no. 11, pp. 5847–5861, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Dejnirattisai, A. Jumnainsong, N. Onsirisakul et al., “Cross-reacting antibodies enhance dengue virus infection in humans,” Science, vol. 328, no. 5979, pp. 745–748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. De La Guardia and R. Lleonart, “Progress in the identification of dengue virus entry/fusion inhibitors,” BioMed Research International, vol. 2014, Article ID 825039, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Jessie, M. Y. Fong, S. Devi, S. K. Lam, and K. T. Wong, “Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization,” Journal of Infectious Diseases, vol. 189, no. 8, pp. 1411–1418, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. S.-J. L. Wu, G. Grouard-Vogel, W. Sun et al., “Human skin Langerhans cells are targets of dengue virus infection,” Nature Medicine, vol. 6, no. 7, pp. 816–820, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Molina-Cruz, L. Gupta, J. Richardson, K. Bennett, W. Black IV, and C. Barillas-Mury, “Effect of mosquito midgut trypsin activity on dengue-2 virus infection and dissemination in Aedes aegypti,” The American Journal of Tropical Medicine and Hygiene, vol. 72, no. 5, pp. 631–637, 2005. View at Google Scholar · View at Scopus
  26. M. I. Salazar, J. H. Richardson, I. Sánchez-Vargas, K. E. Olson, and B. J. Beaty, “Dengue virus type 2: replication and tropisms in orally infected Aedes aegypti mosquitoes,” BMC Microbiology, vol. 7, article 9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Swaminathan and N. Khanna, “Experimental dengue vaccines,” Molecular Vaccines: From Prophylaxis to Therapy, vol. 1, pp. 135–151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Barniol, R. Gaczkowski, E. V. Barbato et al., “Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries,” BMC Infectious Diseases, vol. 11, article 106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Narvaez, G. Gutierrez, M. A. Pérez et al., “Evaluation of the traditional and revised WHO classifications of dengue disease severity,” PLoS Neglected Tropical Diseases, vol. 5, no. 11, Article ID e1397, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. G. Guzman, L. Hermida, L. Bernardo, R. Ramirez, and G. Guillén, “Domain III of the envelope protein as a dengue vaccine target,” Expert Review of Vaccines, vol. 9, no. 2, pp. 137–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S.-W. Wan, C.-F. Lin, S. Wang et al., “Current progress in dengue vaccines,” Journal of Biomedical Science, vol. 20, no. 1, article 37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Bhamarapravati and Y. Sutee, “Live attenuated tetravalent dengue vaccine,” Vaccine, vol. 18, supplement 2, pp. 44–47, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Bhamarapravati, S. Yoksan, T. Chayaniyayothin, S. Angsubphakorn, and A. Bunyaratvej, “Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers,” Bulletin of the World Health Organization, vol. 65, no. 2, pp. 189–195, 1987. View at Google Scholar · View at Scopus
  34. C. Balas, A. Kennel, F. Deauvieau et al., “Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1–4 vaccine virus strains,” Journal of Infectious Diseases, vol. 203, no. 1, pp. 103–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Sun, D. Cunningham, S. S. Wasserman et al., “Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults,” Human Vaccines, vol. 5, no. 1, pp. 33–40, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. V. Watanaveeradej, S. Simasathien, A. Nisalak et al., “Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants,” The American Journal of Tropical Medicine and Hygiene, vol. 85, no. 2, pp. 341–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. S. J. Thomas, K. H. Eckels, I. Carletti et al., “A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults,” The American Journal of Tropical Medicine and Hygiene, vol. 88, no. 1, pp. 73–88, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Bauer, I. O. Esquilin, A. S. Cornier et al., “A phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in puerto rico,” The American Journal of Tropical Medicine and Hygiene, vol. 93, no. 3, pp. 441–453, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. S. S. Whitehead, B. Falgout, K. A. Hanley, J. E. Blaney Jr., L. Markoff, and B. R. Murphy, “A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys,” Journal of Virology, vol. 77, no. 2, pp. 1653–1657, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. S. S. Whitehead, “Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine ?” Expert Review of Vaccines, vol. 15, no. 4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. B. D. Kirkpatrick, S. S. Whitehead, K. K. Pierce et al., “The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model,” Science Translational Medicine, vol. 8, no. 330, Article ID 330ra36, 2016. View at Publisher · View at Google Scholar
  42. A. R. Precioso, R. Palacios, B. Thomé, G. Mondini, P. Braga, and J. Kalil, “Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine,” Vaccine, vol. 33, no. 50, pp. 7121–7125, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. F. Guirakhoo, R. Weltzin, T. J. Chambers et al., “Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates,” Journal of Virology, vol. 74, no. 12, pp. 5477–5485, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. B. Guy, M. Saville, and J. Lang, “Development of sanofi pasteur tetravalent dengue vaccine,” Human Vaccines, vol. 6, no. 9, pp. 696–705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Y.-H. Huang, S. Butrapet, K. R. Tsuchiya, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney, “Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development,” Journal of Virology, vol. 77, no. 21, pp. 11436–11447, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. J. E. Osorio, J. N. Brewoo, S. J. Silengo et al., “Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques,” American Journal of Tropical Medicine and Hygiene, vol. 84, no. 6, pp. 978–987, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. J. E. Osorio, I. D. Velez, C. Thomson et al., “Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study,” The Lancet Infectious Diseases, vol. 14, no. 9, pp. 830–838, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. Takeda. Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children (TIDES), ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine, 2000, https://clinicaltrials.gov/ct2/show/NCT02747927.
  49. R. Putnak, D. A. Barvir, J. M. Burrous et al., “Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys,” The Journal of Infectious Diseases, vol. 174, no. 6, pp. 1176–1184, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. J. R. Putnak, B.-A. Coller, G. Voss et al., “An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model,” Vaccine, vol. 23, no. 35, pp. 4442–4452, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Simmons, T. Burgess, J. Lynch, and R. Putnak, “Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy,” Virology, vol. 396, no. 2, pp. 280–288, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. US Army Medical Research and Materiel Command, “Safety study of a vaccine (DENV-1 PIV) to prevent dengue disease (DENV-1 PIV),” in ClinicalTrials.gov, National Library of Medicine (US), Bethesda, Md, USA, 2000, NLM Identifier: NCT01502735, https://clinicaltrials.gov/ct2/show/NCT01502735. View at Google Scholar
  53. US Army Medical Research and Materiel Command, A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (DPIV-001). In: ClinicalTrials.gov [Internet]. Bethesda, Md, USA, National Library of Medicine (US). 2000- [cited 2016 May 13], NLM Identifier: NCT01666652, https://clinicaltrials.gov/ct2/show/NCT01666652.
  54. US Army Medical Research and Materiel Command, “A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002),” ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine, NLM Identifier: NCT01702857, 2000, https://clinicaltrials.gov/ct2/show/NCT01702857.
  55. US Army Medical Research and Materiel Command, TDENV PIV and LAV Dengue Prime-boost Strategy, ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine (US), NLM Identifier: NCT02239614, 2000, https://clinicaltrials.gov/ct2/show/NCT02239614.
  56. D. E. Clements, B.-A. G. Coller, M. M. Lieberman et al., “Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys,” Vaccine, vol. 28, no. 15, pp. 2705–2715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. D. Govindarajan, S. Meschino, L. Guan et al., “Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates,” Vaccine, vol. 33, no. 33, pp. 4105–4116, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. S. B. Manoff, S. L. George, A. J. Bett et al., “Preclinical and clinical development of a dengue recombinant subunit vaccine,” Vaccine, vol. 33, no. 50, pp. 7126–7134, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. Merck Sharp & Dohme Corp, Study of a Dengue Vaccine (V180) in Healthy Adults (V180-001), ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine (US), NLM Identifier: NCT01477580, 2000, https://clinicaltrials.gov/ct2/show/NCT01477580.
  60. M. Simmons, G. S. Murphy, and C. G. Hayes, “Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine,” The American Journal of Tropical Medicine and Hygiene, vol. 65, no. 2, pp. 159–161, 2001. View at Google Scholar · View at Scopus
  61. L. Hermida, R. Rodríguez, L. Lazo et al., “A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice,” Biotechnology and Applied Biochemistry, vol. 39, no. 1, pp. 107–114, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. L. Hermida, R. Rodríguez, L. Lazo et al., “A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice,” Journal of Virological Methods, vol. 115, no. 1, pp. 41–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Hermida, L. J. Bernardo, M. Martín et al., “A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates,” Vaccine, vol. 24, no. 16, pp. 3165–3171, 2006. View at Google Scholar
  64. J. R. Danko, C. G. Beckett, and K. R. Porter, “Development of dengue DNA vaccines,” Vaccine, vol. 29, no. 42, pp. 7261–7266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. C. G. Beckett, J. Tjaden, T. Burgess et al., “Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial,” Vaccine, vol. 29, no. 5, pp. 960–968, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. K. R. Porter, D. Ewing, L. Chen et al., “Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine,” Vaccine, vol. 30, no. 2, pp. 336–341, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Raviprakash, T. Luke, J. Doukas et al., “A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits,” Human Vaccines and Immunotherapeutics, vol. 8, no. 12, pp. 1764–1768, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. US Army Medical Research and Materiel Command, Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease (TVDV), ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine (US), NLM Identifier: NCT01502358, 2000, https://clinicaltrials.gov/ct2/show/NCT01502358.
  69. K. Raviprakash, D. Wang, D. Ewing et al., “A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus,” Journal of Virology, vol. 82, no. 14, pp. 6927–6934, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. L. J. White, M. M. Parsons, A. C. Whitmore, B. M. Williams, A. de Silva, and R. E. Johnston, “An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice,” Journal of Virology, vol. 81, no. 19, pp. 10329–10339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Brandler, M. Lucas-Hourani, A. Moris et al., “Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus,” PLoS Neglected Tropical Diseases, vol. 1, no. 3, article e96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. D. H. Holman, D. Wang, K. Raviprakash et al., “Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes,” Clinical and Vaccine Immunology, vol. 14, no. 2, pp. 182–189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. N. U. Raja, D. H. Holman, D. Wang et al., “Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector,” American Journal of Tropical Medicine and Hygiene, vol. 76, no. 4, pp. 743–751, 2007. View at Google Scholar · View at Scopus
  74. R. Suzuki, E. R. Winkelmann, and P. W. Mason, “Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2,” Journal of Virology, vol. 83, no. 4, pp. 1870–1880, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Mani, L. Tripathi, R. Raut et al., “Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies,” PLoS ONE, vol. 8, no. 5, Article ID e64595, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. T. J. Chambers, A. Nestorowicz, P. W. Mason, and C. M. Rice, “Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties,” Journal of Virology, vol. 73, no. 4, pp. 3095–3101, 1999. View at Google Scholar · View at Scopus
  77. F. Guirakhoo, K. Pugachev, Z. Zhang et al., “Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates,” Journal of Virology, vol. 78, no. 9, pp. 4761–4775, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. B. Guy, V. Barban, N. Mantel et al., “Evaluation of interferences between dengue vaccine serotypes in a monkey model,” The American Journal of Tropical Medicine and Hygiene, vol. 80, no. 2, pp. 302–311, 2009. View at Google Scholar
  79. S. B. Halstead, “Identifying protective dengue vaccines: guide to mastering an empirical process,” Vaccine, vol. 31, no. 41, pp. 4501–4507, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Guirakhoo, S. Kitchener, D. Morrison et al., “Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes,” Human Vaccines, vol. 2, no. 2, pp. 60–67, 2006. View at Google Scholar
  81. D. Morrison, T. J. Legg, C. W. Billings, R. Forrat, S. Yoksan, and J. Lang, “A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults,” The Journal of Infectious Diseases, vol. 201, no. 3, pp. 370–377, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Z. Capeding, I. A. Luna, E. Bomasang et al., “Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines,” Vaccine, vol. 29, no. 22, pp. 3863–3872, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. G. H. Dayan, M. Thakur, M. Boaz, and C. Johnson, “Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA,” Vaccine, vol. 31, no. 44, pp. 5047–5054, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Sabchareon, D. Wallace, C. Sirivichayakul et al., “Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial,” The Lancet, vol. 380, no. 9853, pp. 1559–1567, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Ghosh and L. Dar, “Dengue vaccines: challenges, development, current status and prospects,” Indian Journal of Medical Microbiology, vol. 33, no. 1, pp. 3–15, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. S. B. Halstead and P. K. Russell, “Protective and immunological behavior of chimeric yellow fever dengue vaccine,” Vaccine, vol. 34, no. 14, pp. 1643–1647, 2016. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Á. Villar, D. M. Rivera-Medina, J. L. Arredondo-García et al., “Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America,” Pediatric Infectious Disease Journal, vol. 32, no. 10, pp. 1102–1109, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. M. R. Capeding, N. H. Tran, S. R. S. Hadinegoro et al., “Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial,” The Lancet, vol. 384, no. 9951, pp. 1358–1365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. S. R. Hadinegoro, J. L. Arredondo-García, M. R. Capeding et al., “Efficacy and long-term safety of a dengue vaccine in regions of endemic disease,” The New England Journal of Medicine, vol. 373, no. 13, pp. 1195–1206, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Villar, G. H. Dayan, J. L. Arredondo-García et al., “Efficacy of a tetravalent dengue vaccine in children in Latin America,” The New England Journal of Medicine, vol. 372, no. 2, pp. 113–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Wilder-Smith and D. J. Gubler, “Dengue vaccines at a crossroad: despite modest ef cacy, a newly developed vaccine may be key for controlling dengue,” Science, vol. 350, no. 6261, pp. 626–627, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. K. W. K. Chan, S. Watanabe, R. Kavishna, S. Alonso, and S. G. Vasudevan, “Animal models for studying dengue pathogenesis and therapy,” Antiviral Research, vol. 123, pp. 5–14, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. R. M. Zellweger and S. Shresta, “Mouse models to study dengue virus immunology and pathogenesis,” Frontiers in Immunology, vol. 5, article 151, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. D. Weiskopf, M. A. Angelo, E. L. De Azeredo et al., “Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 22, pp. E2046–E2053, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Weiskopf and A. Sette, “T-cell immunity to infection with dengue virus in humans,” Frontiers in Immunology, vol. 5, article 93, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. N. Modhiran, D. Watterson, D. A. Muller et al., “Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity,” Science Translational Medicine, vol. 7, no. 304, Article ID 304ra142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. R. P. Beatty, H. Puerta-Guardo, S. S. Killingbeck, D. Glasner, and E. Harris, “Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination,” Science Translational Medicine, vol. 7, no. 304, Article ID 304ra141, 2015. View at Publisher · View at Google Scholar